Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com
StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Free Report) in a report issued on Friday morning. The firm issued a sell rating on the biotechnology company’s stock. Separately, Roth Capital lowered Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Get Our Latest […]
More Stories
Portugal’s Cristiano Ronaldo Announces International Retirement
By The Associated Press Cristiano Ronaldo won’t play for Portugal anymore, ending on Thursday a career that spanned six World...
IRS Unveils 2027 Federal Income Tax Brackets
By Naveen Athrappully Federal tax authorities announced higher income tax brackets and other annual inflation adjustments for tax year 2027....
US Economy Adds 165,000 New Jobs in October, Unemployment Rate Dips to 4.1 Percent
By Andrew Moran Employment conditions strengthened in October as job growth blew past economists’ forecasts and the unemployment rate unexpectedly...
Trump Blames Democrats’ Midterm Victory for Stock Market Losses
By Jack Phillips President Donald Trump on Thursday said a stock market drop that day was due to Democrats winning...
Victor Davis Hanson Discusses What’s Next for GOP, Possible 2028 Contenders
By Timothy Frudd and Jan Jekielek President Donald Trump can still wield considerable political power over the next two years...
US Imposes Sanctions Targeting Iran’s Efforts to Obtain Air Defense Systems
By Timothy Frudd The Trump administration announced new sanctions on Wednesday targeting two individuals and one entity linked to Iran’s...